11H-pyrido[3,2-a]carbazole | 239-06-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 11H-pyrido[3,2-a]carbazole
• CAS: 239-06-5
• 化学式: C₁₅H₁₀N₂
• 分子量: 218.258
• InChiKey: MALZYBOXBVXCSN-UHFFFAOYSA-N

物化性质

• 沸点：
  472.2±18.0 °C(Predicted)
• 密度：
  1.336±0.06 g/cm3(Predicted)
• 熔点：
  334-335 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  11H-pyrido[3,2-a]carbazole 、 3-(4-Chlorophenyl)-7,12-diphenylbenzo[k]fluoranthene 在 dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-3-yl)phosphine 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 邻二甲苯 为溶剂， 反应 2.0h， 以64%的产率得到11-[4-(7,12-Diphenylbenzo[k]fluoranthen-3-yl)phenyl]pyrido[3,2-a]carbazole
  参考文献：
  名称：

  TWI558705

  摘要：

  公开号：
• 作为产物：
  描述：

  5-quinolylhydrazine dihydrochloride 在 palladium on activated charcoal 硫酸 、 sodium acetate 、 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 2.75h， 生成 11H-pyrido[3,2-a]carbazole
  参考文献：
  名称：

  Synthesis of 11H-pyridocarbazoles and derivatives. Comparison of their DNA binding and antitumor activity with those of 6H- and 7H-pyridocarbazoles

  摘要：

  The 8-methoxy- and 8-hydroxy-11H-pyrido[2,3-a]-, -[3,4-a]-, -[4,3-a]-, and [3,2-a]carbazoles were synthesized as potential DNA intercalating antitumor drugs. The structure of these compounds was confirmed by 1H NMR study including NOE experiments. The DNA binding properties of substituted and unsubstituted (8-H) heterocycles were determined by using their hydrochlorides or methiodides. These derivatives are able to bind to DNA with an affinity varying from 2.0 X 10(4) to 1.0 X 10(6) M-1, but most of them are unable to intercalate in contrast with the behavior of 6H- and 7H-pyridocarbazole analogues. The cytotoxicity of 11H-pyridocarbazoles, measured on L1210 cells in vitro, is much lower than those of 6H- and 7H-pyridocarbazole analogues.

  DOI：

  10.1021/jm00159a028

文献信息

• [EN] BIOLOGICAL MATERIALS AND USES THEREOF<br/>[FR] MATÉRIELS BIOLOGIQUES ET LEURS UTILISATIONS
  申请人：ANTIKOR BIOPHARMA LTD

  公开号：WO2016046574A1

  公开（公告）日：2016-03-31

  The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5: 1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

  该发明提供了包含治疗剂与载体分子偶联的化合物，最低偶联比为5:1；其中，载体分子是(i)抗体片段或其衍生物，或(ii)抗体模拟物或其衍生物；治疗剂偶联到赖氨酸氨基酸残基上；进一步，治疗剂不是光敏剂。还提供了关于这些化合物的用途、方法以及其制造过程。
• NaI/PPh₃-Mediated Photochemical Reduction and Amination of Nitroarenes
  作者：Zhonghua Qu、Xing Chen、Shuai Zhong、Guo-Jun Deng、Huawen Huang

  DOI：10.1021/acs.orglett.1c01654

  日期：2021.7.16

  halogen (Cl, Br, and even I), aldehyde, ketone, carboxyl, and cyano. Moreover, the photoredox catalysis with NaI and stoichiometric PPh3 provides also an alternative entry to Cadogan-type reductive amination when o-nitrobiarenes were used.

  发现基于 NaI 和 PPh 3组合的温和无过渡金属和无光敏剂的光氧化还原系统能够高度选择性地还原硝基芳烃。该协议允许广泛的可还原官能团，如卤素（Cl、Br 甚至 I）、醛、酮、羧基和氰基。此外，当使用邻硝基双芳烃时，NaI 和化学计量 PPh 3的光氧化还原催化也提供了 Cadogan 型还原胺化的替代入口。
• METAL COMPLEX PHOSPHATIDYL-INOSITOL-3-KINASE INHIBITORS
  申请人：Meggers Eric

  公开号：US20090275547A1

  公开（公告）日：2009-11-05

  Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase inhibitor. Also disclosed are methods for treating a kinase-affected disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a disclosed organometallic kinase inhibitor.

  提供的是新型有机金属化合物，它们能抑制人黑色素瘤细胞中的PI3K脂质激酶和磷酸化AKT，并且还能抑制黑色素瘤细胞的迁移。本发明还涉及抑制癌细胞增殖、迁移或两者的方法，包括将癌细胞与公开的有机金属激酶抑制剂接触。还公开了治疗激酶相关疾病或状况的方法，包括向有需要的受试者施用治疗有效量的公开的有机金属激酶抑制剂。
• [EN] COMPOUNDS FOR PHOTODYNAMIC THERAPY<br/>[FR] COMPOSÉS POUR THÉRAPIE PHOTODYNAMIQUE
  申请人：REPUBLIC POLYTECHNIC

  公开号：WO2012011875A1

  公开（公告）日：2012-01-26

  A metal-ligand complex comprising a transition metal complexed with at least one Schiff base ligand comprising an additional nitrogen atom from a heterocycle and at least one heteroaromatic nucleic acid intercalating moiety. A pharmaceutical composition comprising the compound in admixture with a pharmaceutically acceptable carrier togther with use of the compound in the treatment of cancer, macular degeneration, human papilloma virus (HPV) warts and a skin disorder is also provided.

  一种金属配体络合物，包括与至少一种席夫碱配体络合的过渡金属，该配体包括来自杂环的额外氮原子和至少一种杂芳核酸插入基团。还提供了一种药物组合物，其中包含该化合物与药用可接受载体混合，并且还提供了该化合物在治疗癌症、黄斑变性、人类乳头瘤病毒（HPV）疣和皮肤疾病中的用途。
• Bis-carbazole DNA intercalating agents for antitumor therapy
  申请人：Gribble Gordon W.

  公开号：US20100010033A1

  公开（公告）日：2010-01-14

  The present invention is a DNA intercalating agent represented by the structure Y-Z-Y, wherein Y is an anti-tumor bis-carbazole and Z is a linear arrangement of multiple aromatic rings, containing at least two aromatic rings, or at least two alicyclic rings, said rings being linked in a 1,4 or 1,3 manner. Methods of inhibiting cancer cells and treating subjects having cancer with these agents are also provided.

  本发明是一种DNA插入剂，其结构表示为Y-Z-Y，其中Y是一种抗肿瘤双咔唑，Z是多个芳香环的线性排列，含有至少两个芳香环或至少两个脂环，这些环以1,4或1,3方式连接。还提供了使用这些药剂抑制癌细胞和治疗患有癌症的受试者的方法。